In medical news:

The New Drug Application for a new sublingual spray formulation of buprenorphine to treat moderate to severe acute pain has been rejected by the FDA. Insys Therapeutics confirmed in a press release that it received a Complete Response Letter from the agency regarding its application.

Read more via Pain Medicine News here.

Leave a Comment

Your email address will not be published. Required fields are marked *